All Type of News
Rumors about next Chair of the KPBMA, what is the reality?
Heng-Myung Lee, Chair of the Board of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA), decided not to continue his position, there have been many rumors about the next chair.
First of all, th...
Medicine payment obligation spreads credit card payments among hospitals
While the Payment Due for Medicines bill has been enforced on the last 23rd, pharmaceutical distribution companies have complained difficulties about an increasing number of hospitals which switch the method of paymen...
It’s time for pharma & biotech industry to answer, “2018 is Year with Outcomes”
Pharmaceutical companies have set 2018 as the ‘Year with Outcomes’ from researches and developments they have conducted so far.
Each pharmaceutical company has not officially revealed their management plan yet, but a...
Hanall, “We received USD 30 million upfront payment for technology export from Roivant”
Hanall Biohparma(CEO Seung-Gook Park, Jae-Choon Yoon) announced “We received the USD 30 million(approx. KRW 32.4 billion) upfront payment for its autoimmune disease antibody(HL161) technology agreement from Roivant Sc...
Oscotec applies for U.S. clinical 2a IND of its rheumatoid arthritis treatment
Oscotec(CEo Jung-Geun Kim), a new drug developing company, announced on the 26th that the company applied for a IND for a clinical 2a study to the U.S. FDA as completing Phase I SAD(single ascending dose) & MAD(multip...
MFDS designations of 4 additional orphan drugs including lung cancer therapy ‘Brigatinib’
4 medicines, including ‘Brigatinib,’ a targeted therapy for lung cancer, were designated as orphan drug.
The Ministry of Food and Drug Safety(MFDS) pre-announced the ‘Partial Revision Bill to Regulations of Orphan Dr...
121 products newly registered for national health insurance service
121 products including ‘Ganilever Prefilled Syringe Inj’ which prevents premature luteinizatio will take an advantage, of the health insurance benefits as being registered for the national health insurance service.
‘...
Alteogen challenges to KRW 1.8 trillion acromegaly treatment market with Severance Hospital
Alteogen(Soon-Jae Park), a company developing antibody biobetters, announced on the 22nd that the company has signed a co-development agreement of an acromegaly treatment using NexP™-based growth hormone receptors wit...
SK to target the KRW 1 trillion global market of sleep disorder treatments
SK Biopharmaceuticals announced on the 21st the company completed the NDA(New Drug Application) process to the U.S. FDA for SKL-N05(generic name: Solriamfetol) with U.S. Jazz Pharmaceuticals, the world’s leading compa...
Genexine succeeds in transferring ‘Interleukin 7’ technology worth of total USD 560 million
Genexine succeeded in transferring technology worth of total USD 560 million.
Genexine publicly announced the company signed a technology transfer agreement of ‘Interleukin 7(long-acting IL-7 cytokine designated as ...
